4.7 Article

Ultrasmall iron oxide nanoparticles cisplatin (IV) prodrug nanoconjugate: ICP-MS based strategies to evaluate the formation and drug delivery capabilities in single cells

期刊

ANALYTICA CHIMICA ACTA
卷 1159, 期 -, 页码 -

出版社

ELSEVIER
DOI: 10.1016/j.aca.2021.338356

关键词

Iron oxide nanoparticles; Cisplatin (IV) prodrug; Nano-conjugate; Single cell ICP-MS

资金

  1. Spanish Ministry of Education, Culture and Sports (MECD) [FPU15/02415]
  2. government of Asturias through the Science, Technology and Innovation Plan (PCTI) - FEDER funds [FC-GRUPIN-IDI/2018/000242]
  3. Spanish Ministry of Economy, Industry and Competitiveness (MINECO) [CTQ2016-80069-C 2-1R, RTI2018-094605-B-I00]

向作者/读者索取更多资源

Ultrasmall iron oxide nanoparticles were used as nanotransporters for cisplatin prodrug in cellular models, forming stable conjugates. Different techniques were used to characterize the nanoconjugate, and single cell-ICP-MS was employed to explore cellular uptake. The nanoconjugate exhibited higher intracellular platinum concentrations and DNA platination levels compared to cisplatin, showing potential for overcoming drug resistance.
Ultrasmall iron oxide nanoparticles (<10 nm) were explored here as nanotransporters of cis-diamminetetrachloroplatinum (IV) (a cisplatin prodrug) in cellular models. The coating of the particles containing reactive carboxylic acid groups enabled the formation of a stable conjugate between the prodrug and the nanoparticles using one pot reaction. The nanoconjugate was characterized by different techniques exhibiting diameters of about 6.6 ? 1.0 nm. The use of a hyphenated strategy based on high performance liquid chromatography (HPLC) coupled to inductively coupled plasma mass spectrometry (ICP-MS) permitted the quantitative evaluation of Fe and Pt in the nanoconjugate. Furthermore, the cellular uptake of the synthetic nanoconjugate was explored by single cell-ICP-MS (SC-ICP) which was used for the first time in this type of studies. The experiments in A2780 and A2780cis, sensitive and resistant ovarian cancer cell models respectively, revealed intracellular platinum concentrations of 12 fg/ cell and 4 fg/cell, respectively which were 4-fold higher with respect to the uptake of cisplatin in both models. Intracellular drug release from the nanoconjugate was proved by measuring DNA platination in the same cells. In this case, levels of about 250 ng Pt/mg DNA were observed, about 5-fold higher when the nanoconjugate was used in comparison to cisplatin. Furthermore, the differences between the two lines turned to be significantly smaller than in the case of using cisplatin. The quantitative analytical tools developed here provided essential information required to fully characterize the developed nanoplatforms particularly important to overcome drug resistance. (c) 2021 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据